

Supplemental Table 1

Frequency of immune-related adverse events (irAEs) in the present study and in a previous study (17)

Ipilimumab dose	Patients experiencing grade ≥ 3 irAEs / patients treated at this dose			
	Present study (n=)	%	Prior study(n=)	%
3 mg/kg	3/15	20%	19/131	15%
10 mg/kg	6/14	43%	18/71	25%